TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8951132
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 (PGE2) gel (two doses of 0.5 mg)
Study: 2021677
Drug: Alcohol ingestion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol ingestion (two dosage levels)
Study: 27605038
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calorie restriction and exercise (7% weight loss over 3-6 months)
Study: 27281448
Drug: Ambroxol Lozenges
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol Lozenges (AXL20) 20mg
Study: 27281448
Drug: Placebo Lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lozenges (PL)
Study: 22983495
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of features from multiple ERP components
Study: 19572937
Drug: Paracetamol 2
Normalized name: Paracetamol 24 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 2 g
Study: 7981460
Drug: Droloxifene 20
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 20 mg daily
Study: 7981460
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg daily
Study: 7981460
Drug: Droloxifene 100
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 100 mg daily
Study: 23704673
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (M)
Study: 23704675
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus intensive lifestyle program (M+L)
Study: 23704673
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus rosiglitazone (M+R)
Study: 23704675
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (M, M+R, M+L)
Study: 17909125
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fluoxetine + CBT)
Study: 20631556
Drug: Fluoxetine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine therapy
Study: 15911154
Drug: Behavioural medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural medicine rehabilitation (PT+CBT)
Study: 15911154
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control group (CG)
Study: 11306379
Drug: MMP-2 excretion
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP-2 excretion
Study: 11306379
Drug: MMP-9 excretion
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP-9 excretion
Study: 9330417
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol through a neonatal Aerochamber with non-rebreathing valve
Study: 9330417
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol through a neonatal Aerochamber without non-rebreathing valve
Study: 9330417
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol through Babyhaler with one-way inspiratory valve
Study: 9330417
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol through Babyhaler without one-way inspiratory valve
Study: 22527287
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (DS) containing Red yeast rice (RYR), sugar cane‐derived policosanols (SCdP), and artichoke leaf extracts (ALEs)
Study: 10385662
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy (IFN‐alpha for up to 32 weeks)
Study: 10385662
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (IFN‐alpha for 16 weeks)
Study: 6441537
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg piribedil intravenously over a 15 min period
Study: 6441537
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor blocking agent, haloperidol (pretreated group)
Study: 20006921
Drug: Z‐360 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐360 120 mg
Study: 20006921
Drug: Z‐360 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐360 240 mg
Study: 20006921
Drug: Z‐360 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐360 (both doses)
Study: 14727947
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus a statin (lovastatin, pravastatin, atorvastatin, or simvastatin)
Study: 441686
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of fluphenazine enanthate
Study: 441686
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of fluphenazine enanthate
Study: 17823681
Drug: Co-curing the
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-curing the bonding agent with resin composite (Group COC)
Study: 11529355
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) treatment: 250 mg ZDV orally twice a day starting at 38 weeks' gestation until labor, plus ZDV infusion at 2 mg/kg during the first hour of labor and then 1 mg/kg/h until delivery.
Study: 11529355
Drug: Placebo treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment: identical capsule during pregnancy and normal saline infusion during labor until delivery.
Study: 7461330
Drug: Initial 'empiric'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial 'empiric' dosage followed by 'rational' maintenance (group IV)
Study: 31888691
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention (Fear Reduction Efficacy Evaluation [FREE]) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Study: 31888691
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group receiving diabetes self-management education (DSME) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Study: 31888691
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention (FREE)
Study: 26356708
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 IU once daily
Study: 26356708
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) 5000 IU twice daily
Study: 17600649
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm guess
Study: 16636358
Drug: Sucrose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (2 mL)
Study: 12748500
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol replacement
Study: 12940591
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol replacement
Study: 10978944
Drug: Lactase tablets
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase tablets
Study: 8595970
Drug: timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5% twice a day (b.i.d.)
Study: 7034473
Drug: Metoprolol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 15 mg IV followed by a total daily dose of 200 mg/day
Study: 28673363
Drug: RYR-olive extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RYR-olive extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Study: 23298376
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day for 14 days
Study: 19302635
Drug: Esmolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1 mg.kg(‐1) bolus followed by 250 microg.kg(‐1)min(‐1) infusion)
Study: 17515571
Drug: Radiotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy only or nonalkylating chemotherapy (ABVD, EBVP)
Study: 17515571
Drug: Chemotherapy containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy containing alkylating agents (MOPP, ABV, BEACOPP)
Study: 17515571
Drug: Nonalkylating chemotherapy
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonalkylating chemotherapy
Study: 17515571
Drug: Alkylating chemotherapy
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating chemotherapy
Study: 17515571
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of alkylating chemotherapy
Study: 11472042
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (open surgical or endovascular procedures)
Study: 9492829
Drug: 5'-deoxy-5-fluorouridine (5'-DFUR)
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-deoxy-5-fluorouridine (5'-DFUR) administration at a dose of 1,200 mg/body for 7 days
Study: 8049831
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch delivering 11 mg of nicotine over 24 hours
Study: 25500202
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g inulin-propionate ester
Study: 25500202
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day inulin-propionate ester supplementation
Study: 23363981
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no probucol treatment)
Study: 18436353
Drug: Intradermal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal immunization (0.1 ml of trivalent influenza vaccine)
Study: 18436353
Drug: Intradermal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal immunization
Study: 18436353
Drug: Subcutaneous immunization
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunization (0.1 ml of trivalent influenza vaccine)
Study: 18436353
Drug: Subcutaneous immunization
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunization
Study: 14510756
Drug: Ionic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic low osmolar agent
Study: 14510756
Drug: Non-ionic, iso-osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ionic, iso-osmotic agent
Study: 14510756
Drug: Non-ionic, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ionic, low osmolar agent
Study: 3083851
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (350 mg intravenously)
Study: 3083851
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (1200 mg daily for 3 days)
Study: 3083851
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (60.7 mg kg‐1 for 8 days)
Study: 3083851
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (52.6 mg kg‐1 for 8 days)
Study: 29898752
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and chemotherapy (Arms B and C)
Study: 29898752
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Arm A)
Study: 28115966
Drug: Walnut oil
Normalized name: Walnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut oil (15 g/day for three months)
Study: 21265206
Drug: Hook needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hook needle knife treatment
Study: 17935553
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (1000 mg/day)
Study: 15736119
Drug: Low rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low rate of insulin infusion (1.5 mU insulin/kg per minute)
Study: 15736119
Drug: High rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High rate of insulin infusion (15 mU insulin/kg per minute)
Study: 12137603
Drug: ACEI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI group (benazepril 10 mg/d)
Study: 2550045
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg oral)
Study: 2550045
Drug: Perindoprilat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (2 mg intravenously)
Study: 2550045
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg oral) and Perindoprilat (2 mg intravenously)
Study: 4608503
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) therapy
Study: 30985244
Drug: PPIC 2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIC 2.1 survey administered to beneficiaries
Study: 29717841
Drug: Triple acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple acupuncture at the Qugu acupoint (twice a week for 4 weeks)
Study: 29717841
Drug: Levofloxacin Mesylate
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Mesylate Tablets (0.5 g, tid) + Terazosin Hydrochloride Capsules (2 mg qd) for 4 weeks
Study: 18413983
Drug: Venous thromboembolism
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous thromboembolism prophylaxis (mechanical, pharmacological, or a combination of both)
Study: 1612952
Drug: Hypothalamic‐pituitary radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothalamic‐pituitary radiation therapy
Study: 6145533
Drug: Prenalterol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (1 mg/hr)
Study: 6145533
Drug: Prenalterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (2 mg/hr)
Study: 6145533
Drug: Salbutamol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (low dose)
Study: 23147138
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of RIX4414 vaccine (n = 328)
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 1 μg/mL
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 2 μg/mL
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 3 μg/mL
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 4 μg/mL
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 5 μg/mL
Study: 21056809
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 6 μg/mL
Study: 9882082
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 50 mg
Study: 14570662
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion (30 microg/h)
Study: 14570662
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl infusion (30 microg/h)
Study: 11115439
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution perfusion
Study: 9175684
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in pre-eclampsia group
Study: 9175684
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in uncomplicated pregnancy group
Study: 1564652
Drug: Conventional monofocal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional monofocal implant
Study: 3890786
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy alone (32 patients)
Study: 3890786
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy plus BCG vaccine (24 patients)
Study: 3890786
Drug: Ten-day chemotherapy
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day chemotherapy (vincristine sulfate, cytarabine, prednisone)
Study: 3890786
Drug: Five-day chemotherapy
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day chemotherapy (cytarabine)
Study: 28710229
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of antibiotic therapy
Study: 30831300
Drug: Diagnostic transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic transforaminal epidural injection (DTEI)
Study: 24368436
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g LNS/d
Study: 24368436
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g LNS/d
Study: 24368436
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g LNS/d
Study: 24481578
Drug: Subcutaneously implanted
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously implanted epidural ports (SIEP) with morphine administration (starting with 2 mg, maximum 4 mg per day)
Study: 24481578
Drug: Subcutaneously implanted
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously implanted epidural ports (SIEP) with morphine administration
Study: 22627883
Drug: FEIBA (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEIBA (lower doses)
Study: 17056272
Drug: Cuban recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuban recombinant hepatitis B vaccine (Heberbiovac HB), 20 microg HBsAg/mL, administered in three doses at month 0, 1, and 2.
Study: 17134634
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in white patients
Study: 17134634
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in black patients
Study: 12565987
Drug: 5-FU 60
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 60 mg/kg as a continuous infusion over 48 h, with methotrexate 40 mg/m(2) administered just before 5-FU (control regimen)
Study: 12565987
Drug: PALA 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 250 mg/m(2) as a 15 min infusion administered 24 h before 5-FU and methotrexate
Study: 1328817
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 g/d for 4 weeks)
Study: 1328817
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (15 g/d for 4 weeks)
Study: 4062571
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 gm twice daily, p.m. dose at different times
Study: 4062571
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 gm twice daily, p.m. dose 30 minutes before evening meal
Study: 4062571
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 gm twice daily, p.m. dose mid-afternoon
Study: 4062571
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 gm twice daily, all treatment periods
Study: 23588485
Drug: Self-administered PNF
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered PNF hamstring stretching 2 × 40 seconds on each leg for 6 weeks
Study: 18083322
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy for pregnant substance users (MET‐PS)
Study: 10703890
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (verapamil 180 mg plus trandolapril 2 mg)
Study: 10703890
Drug: Monotherapy (dose-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (dose-titration or switching to a different drug class)